Literature DB >> 23574319

Ro52- and Ro60-specific B cell pattern in the salivary glands of patients with primary Sjögren's syndrome.

L A Aqrawi1, K Skarstein, G Øijordsbakken, K A Brokstad.   

Abstract

Primary Sjögren's syndrome (pSS) is characterized by the presence of autoantibodies against the ribonucleoprotein (RNP) particles Ro/SSA and La/SSB, and mononuclear cell infiltration of exocrine tissues, especially salivary and lachrymal glands. Low numbers of autoantigen-specific memory B cells and elevated levels of plasma cells have been detected previously in the peripheral blood (PB) of pSS patients compared to controls. As both Ro52 and Ro60-specific cells have been detected in the salivary glands (SG) of pSS patients, we aimed to characterize the SSA-specific B cell pattern in SG biopsies. A series of double immunohistochemical stainings were performed on paraffin-embedded tissue from 10 well-characterized pSS patients for each Ro52 and Ro60 along with CD19, CD5, CD20 or CD27, respectively. Ro52 and Ro60-specific cells detected in SG tissue were found to be CD19(+) B cells located outside the CD19(+)/CD20(+) B cell zones (BCZ) and also interstitially. These SSA-specific cells were also quantified. No SSA-specific cells were CD5(+), indicating that they do not belong to the B-1 B cell subset. Furthermore, no SSA-specific cells were observed within the CD20(+) BCZ. Hence, no SSA-specific memory B cells were detected in these individuals. Contrary to this, SSA-specific cells were found to be CD19(+)/CD27(++), demonstrating that they are differentiating short or long-lived plasma cells. Taken together, our findings suggest that these lower levels of SSA-specific memory B cells in PB and absence of SSA-specific memory B cells in SG of pSS patients could result from activation of these cells into plasma cells at the site of inflammation.
© 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23574319      PMCID: PMC3628325          DOI: 10.1111/cei.12058

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

1.  Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.

Authors:  Therese Vallerskog; Iva Gunnarsson; Mona Widhe; Anke Risselada; Lars Klareskog; Ronald van Vollenhoven; Vivianne Malmström; Christina Trollmo
Journal:  Clin Immunol       Date:  2006-10-13       Impact factor: 3.969

2.  Humoral immunity due to long-lived plasma cells.

Authors:  M K Slifka; R Antia; J K Whitmire; R Ahmed
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

3.  Ro/SS-A-reactive B lymphocytes in salivary glands and peripheral blood of patients with Sjögren's syndrome.

Authors:  A Halse; J B Harley; U Kroneld; R Jonsson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

4.  The serological pattern of autoantibodies to the Ro52, Ro60, and La48 autoantigens in primary Sjögren's syndrome patients and healthy controls.

Authors:  H Garberg; R Jonsson; K A Brokstad
Journal:  Scand J Rheumatol       Date:  2005       Impact factor: 3.641

Review 5.  Role of B cells in Sjögren's syndrome--from benign lymphoproliferation to overt malignancy.

Authors:  Roland Jonsson; Elisabeth Nginamau; Ewa Szyszko; Karl A Brokstad
Journal:  Front Biosci       Date:  2007-01-01

6.  B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles.

Authors:  G Cambridge; M J Leandro; M Teodorescu; J Manson; A Rahman; D A Isenberg; J C Edwards
Journal:  Arthritis Rheum       Date:  2006-11

7.  Low number of memory B cells in the salivary glands of patients with primary Sjögren's syndrome.

Authors:  Lara A Aqrawi; Karl A Brokstad; Kjerstin Jakobsen; Roland Jonsson; Kathrine Skarstein
Journal:  Autoimmunity       Date:  2012-09-05       Impact factor: 2.815

Review 8.  Sjögren's syndrome--a plethora of clinical and immunological phenotypes with a complex genetic background.

Authors:  Roland Jonsson; Anne Isine Bolstad; Karl A Brokstad; Johan G Brun
Journal:  Ann N Y Acad Sci       Date:  2007-06       Impact factor: 5.691

Review 9.  B lymphocytes on the front line of autoimmunity.

Authors:  Pierre Youinou; Sophie Hillion; Christophe Jamin; Jacques-Olivier Pers; Alain Saraux; Yves Renaudineau
Journal:  Autoimmun Rev       Date:  2005-08-16       Impact factor: 9.754

10.  Differential expression of Ro/SSA 60 kDa and La/SSB, but not Ro/SSA 52 kDa, mRNA and protein in minor salivary glands from patients with primary Sjögren's syndrome.

Authors:  Karin S A Barcellos; Suely Nonogaki; Milvia M S S Enokihara; Miriam S Teixeira; Luís E C Andrade
Journal:  J Rheumatol       Date:  2007-06       Impact factor: 4.666

View more
  9 in total

1.  Interaction between innate immunity and Ro52-induced antibody causes Sjögren's syndrome-like disorder in mice.

Authors:  Barbara M Szczerba; Paulina Kaplonek; Nina Wolska; Anna Podsiadlowska; Paulina D Rybakowska; Paromita Dey; Astrid Rasmussen; Kiely Grundahl; Kimberly S Hefner; Donald U Stone; Stephen Young; David M Lewis; Lida Radfar; R Hal Scofield; Kathy L Sivils; Harini Bagavant; Umesh S Deshmukh
Journal:  Ann Rheum Dis       Date:  2015-02-05       Impact factor: 19.103

Review 2.  Biologic therapy in Sjögren's syndrome.

Authors:  Qin Shao
Journal:  Clin Rheumatol       Date:  2020-10-27       Impact factor: 2.980

3.  Ductal epithelial expression of Ro52 correlates with inflammation in salivary glands of patients with primary Sjögren's syndrome.

Authors:  L A Aqrawi; M Kvarnström; K A Brokstad; R Jonsson; K Skarstein; M Wahren-Herlenius
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

Review 4.  A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity.

Authors:  Adrian Y S Lee
Journal:  Rheumatol Int       Date:  2017-04-17       Impact factor: 2.631

Review 5.  Contributions of Major Cell Populations to Sjögren's Syndrome.

Authors:  Richard Witas; Shivai Gupta; Cuong Q Nguyen
Journal:  J Clin Med       Date:  2020-09-22       Impact factor: 4.241

6.  CP-25 alleviates antigen-induced experimental Sjögren's syndrome in mice by inhibiting JAK1-STAT1/2-CXCL13 signaling and interfering with B-cell migration.

Authors:  Huaxun Wu; Xiaoyun Chen; Fang Gu; Pengying Zhang; Shixia Xu; Qi Liu; Qiaolin Zhang; Xinming Wang; Chun Wang; Heinrich Körner; Wei Wei
Journal:  Lab Invest       Date:  2020-07-03       Impact factor: 5.502

7.  Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome.

Authors:  Saba Nayar; Joana Campos; Charlotte G Smith; Valentina Iannizzotto; David H Gardner; Serena Colafrancesco; Elena Pipi; Florian Kollert; Kelly J Hunter; Charlotte Brewer; Christopher Dominic Buckley; Simon J Bowman; Roberta Priori; Guido Valesini; Maria Juarez; William A Fahy; Benjamin A Fisher; Andrew Payne; Rodger A Allen; Francesca Barone
Journal:  Ann Rheum Dis       Date:  2018-11-24       Impact factor: 19.103

Review 8.  B cell dysregulation in primary Sjögren's syndrome: A review.

Authors:  Hazim Mahmoud Ibrahem
Journal:  Jpn Dent Sci Rev       Date:  2019-10-21

9.  Common and specific associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies in systemic lupus erythematosus.

Authors:  Aurora Menéndez; Jesús Gómez; Luis Caminal-Montero; José Bernardino Díaz-López; Iván Cabezas-Rodríguez; Lourdes Mozo
Journal:  ScientificWorldJournal       Date:  2013-10-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.